Winsunv Bio-B (02630.HK): The marketing registration application (NDA) for Angweida Semenafil Hydrochloride Tablets has been accepted by the Hong Kong Department of Health and the Macao Pharmaceutical Administration Bureau.

Zhitong Finance APP News, Wangshan Wangshui-B (02630.HK) announced that recently, the New Drug Application (NDA) for the Class 1 new drug simenafil hydrochloride tablets (trade name: Angweida, development code: TPN171), independently developed by the Group, for the treatment of erectile dysfunction (ED) has been officially accepted by the Department of Health of Hong Kong for marketing in the Hong Kong Special Administrative Region of China; the NDA in the Macao Special Administrative Region of China was also officially accepted by the Pharmaceutical Administration Bureau on September 30, 2026.